Lancaster General Hospital
The aim of this study is to see if administering platelets (cells in our blood that stop or prevent bleeding) results in improved platelet function and slows/stops the progression of a head bleed for patients who have a traumatic head bleed and are on antiplatelet therapy (medications that stop blood cells from forming a blood clot) prior to admission.
This study aims to determine if platelet function has improved following platelet transfusion by prospectively performing repeat thromboelastographic with platelet mapping (TEG-PM) assays on all patients consented and enrolled in the study. This study will also examine the rate of progression or stability of ICH on repeat head CT following platelet administration and will aid in the determination of a potential association between repeat CT head findings and the repeat TEG-PM results.
Inclusion Criteria for Interventional Portion of Study: * Patients ≥ 18 years of age who present with TICH meeting Brain Injury Guidelines (BIG) 2 or 3 head bleed criteria * Currently on antiplatelet medication on admission * Must have taken this antiplatelet medication within the past 48 hours prior to presentation * Patients who have AA and/or ADP inhibition of 70% or greater and Maximum Amplitude (MA) \<50 will then receive a platelet transfusion and a repeat TEG-PM 1hr after transfusion Exclusion Criteria for Interventional Portion of Study: * Under 18 years of age * Have a known bleedi…
Thromboelastography (TEG) is an assay used by many medical professionals to assess coagulopathy, predict outcomes, and guide treatment. Although TEG does not assess platelet function very well, a TEG with platelet mapping (TEG-PM) assay assesses platelet functioning by measuring the percent of arachidonic acid (AA) and adenosine diphosphate (ADP) that are inhibited in the patient's blood.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.